Metastatic Rcc: Using Frontline Ipilimumab/Nivolumab

Metastatic RCC: Using Frontline Ipilimumab/Nivolumab

FDA Approval of Frontline Nivolumab/Ipilimumab Combo in RCC

Dr. Pal on the Frontline Approval of Nivolumab and Ipilimumab in mRCC

Frontline Therapy Options for mRCC

Targeted Oncology

mRCC Patient Selection for Ipilimumab/Nivolumab

Dr. McDermott on Nivolumab Plus Ipilimumab in RCC

Dr. McKay on FDA Approval of Nivolumab/Ipilimumab in Frontline RCC

RADVAX: Nivolumab / ipilimumab with SBRT for metastatic renal cell carcinoma

Optimizing the Use of Ipilimumab/Nivolumab in mRCC

Nivolumab and Ipilimumab Combination in Frontline mCRC

Targeted Oncology

Dr. Motzer on Nivolumab/Ipilimumab Activity in RCC

Nivolumab and ipilimumab for metastatic kidney cancer

Front-line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced RCC

Ipilimumab/Nivolumab in First-Line mRCC

Nivolumab with ipilimumab for mRCC

Combination Therapies Emerge in the Frontline for Renal Cell Carcinoma

Targeted Oncology

CHECKMATE 920: nivolumab plus ipilimumab for renal cell cancer

Investigating Responses to Nivolumab and Ipilimumab in Advanced RCC

Targeted Oncology

Frontline Treatment Standard in mRCC

Targeted Oncology

Treatment-free survival results of nivolumab and salvage nivolumab + ipilimumab for accRCC